CONTEXT: Continuing this years theme of presenting RWR posters alongside traditional RCTs, Teva showed off their AJOVY (fremanezumab-vfrm) treatment for migraine at the American Headache Society annual meeting. Also included in the posters was RWR on AJOVY’s impact on comorbid depression and anxiety
IMPACT: low
READ TIME: 4. Mins
Quality Level Mean [1 – 10]: 8
1. “These analyses and extension studies of our landmark HALO and FOCUS clinical programs, evaluating AJOVY over the course of 15 months and the efficacy in patients who’ve failed prior treatments, reinforce the potential AJOVY can have for patients living with migraine,” said Joshua M. Cohen, MD, MPH, FAHS, Global Medical Therapeutic Area Lead for Migraine Headache, Teva.”
2. “TEL AVIV, Israel PARSIPPANY, N. J–(BUSINESS”
3. “WIRE)–Teva Pharmaceuticals USA, Inc. , a U. S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY (fremanezumab-vfrm) for the treatment of migraine, which is being presented at the American Headache Society (AHS) annual meeting, taking place virtually on June 3-6.”
4. “AJOVY is the first and only long-acting anti-CGRP subcutaneous injection approved in the US for the preventive treatment of migraine in adults that offers both quarterly and monthly dosing options.”
5. “3+± Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine Over the Course of 15 Months Patients who completed the Phase 3 HALO EM and CM clinical trial, along with new patients, entered the HALO long-term study”